Complication rate after implant-based breast-reconstruction with support of a synthetic non-resorbable titanized polypropylene mesh (TiLOOP® Bra): Analysis of the 2-year follow up from the prospective multicentre PRO-BRA trial Authors: Marc Thill, Evelyn Klein, Elke Nolte, Jan Forster, Christine Ankel, Claudia Gerber-Schäfer, Kristin Baumann, Anette Meiré, Christine Mau, Jens-Uwe Blohmer, Andree Faridi, Stefan Paepke Published: 2026 ABSTRACT BackgroundSpecific patient characteristics and certain cancer treatments increase the risk for postoperative complications in implant-based breast reconstructions. It is therefore essential to identify those risk factors and analyse their contribution to the outcome.MethodsImplant-based breast reconstruction with support of synthetic non-resorbable titanized polypropylene surgical mesh (TiLOOP® Bra) was performed in 269 patients during the prospective, multicentre PRO-BRA cohort trial (clinicaltrials.gov: NCT01885572, DRKS: DRKS00005342). Secondary endpoint was the evaluation of the postoperative complication rate 24 months after breast reconstruction. Univariable and multivariable logistic regression analyses were performed to identify specific factors (e.g. BMI, age, radiotherapy, chemotherapy, implant size) increasing the risk for complications.ResultsIn 362 breast reconstructions the following factors were identified in univariable logistic regression to be associated with an increased risk for distinct complications: Implant volume, BMI (complication irrespective of type, seroma, wound complications), adjuvant radiotherapy (capsular fibrosis), Charlson Comorbidity Index (first complication, seroma), age (seroma), transverse/vertical incision (wound complications), and adjuvant chemotherapy (infection/inflammation). Multivariable logistic regression identified neoadjuvant chemotherapy as significant risk factor for the occurrence of complications.ConclusionThe following factors have been identified as increasing the risk of developing postoperative complications of implant-based breast reconstruction with a non-resorbable titanized polypropylene surgical mesh (TiLOOP® Bra): larger implants, age of 50 years or over, BMI of 25 kg/m2 or over, adjuvant radiotherapy, as well as neoadjuvant and adjuvant chemotherapy. These factors must be considered when selecting patients for this type of breast reconstruction and should form part of a thorough patient information. Introduction Immediate breast reconstruction has been shown to provide psychological benefits and to be oncologically safe.1,2 The implant-based breast reconstruction (IBBR) technique has the advantage of reducing patient stress due to a shorter operation and hospitalisation times.3, 4, 5 Once the mastectomy is complete, a pocket is formed beneath the pectoralis major muscle into which the implant is placed. Therefore, the outcome of the reconstruction is limited by the availability and quality of the muscle, as this must cover and create a complete subpectoral pocket for the breast prosthesis. Disadvantages of the subpectoral implant placement include sparse or insufficient coverage of the prosthesis, which can result in impaired skin and a higher rate of follow-up operations.6 This can be avoided by inserting supporting, covering or interposing materials.7 These supporting materials include biological acellular dermal matrices and synthetic meshes; which are widely used in IBBR to support the lower pole of the breast and to define the inframammary fold.8 While complications are inherent in any surgical technique, the most frequently described early complications after breast reconstruction are positive margins, necrosis, infection, haematoma, bleeding, seroma, and wound healing disturbances or a combination of these.9, 10, 11, 12 Furthermore, capsular fibrosis is the most common complication after breast reconstruction and one of the most common reasons for reoperation.13 Previous studies have already aimed to identify patient characteristics that potentially lead to complications during the post-reconstructive period. Patient characteristics and surgical methods that have been correlated with an increased risk of postoperative complications include age, diabetes, higher body mass index (BMI), smoking, and reconstruction type (autologous versus implant reconstruction).14,15 The multicentre, national, prospective Patient Reported Outcome (PRO)-BRA trial investigated IBBR, supported by the TiLOOP® Bra, a titanized non-resorbable polypropylene mesh. One of the study’s aims was to evaluate postoperative complications in detail and identify potential risk factors that could contribute to the decision-making process of surgeons and patients. Although the surgical mesh examined in this study has been in clinical use since 2008 and the data were collected between 2013 and 2018, the publication of these findings remains highly relevant for contemporary practice. While reconstructive techniques have evolved, particularly with increasing uptake of prepectoral approaches, the core indications, biological interactions, and complication mechanisms associated with mesh-assisted implant reconstruction have remained broadly comparable. This analysis represents the largest multicentric, prospective cohort using a uniform TiLOOP® Bra technique in both immediate and delayed IBBR with a long-term, 24-months follow-up. Material and methods Study design and study population The “PRO-BRA - National, multicentre post-market surveillance study ´Patient Reported Outcome´ in breast reconstruction following mastectomy with titaniferously coated polypropylene mesh (TiLOOP® Bra)” (clinicaltrials.gov: NCT01885572, DRKS: DRKS00005342) is a prospective, single-arm, multi-centre study performed in eight German centres according to the declaration of Helsinki. Ethical approval was obtained from the institutional ethics committee from the faculty of medicine, Technical University Munich, Germany (# 5890/13), as the leading ethics committee as well as from the respective ethics committees from the remaining study sites. Between December 2013 and December 2016, 269 women who underwent skin-sparing, nipple-sparing or modified radical mastectomy with immediate or delayed subpectoral IBBR with TiLOOP® Bra mesh support (pfm medical gmbh, Cologne, Germany), were included. This is a large-pore extra-light mesh made from titanized monofilament polypropylene thread. Inclusion criteria were an indication for prophylactic or therapeutic oncological surgery, a strong family history or a genetic predisposition. Exclusion criteria were pregnancy or breastfeeding, metastatic breast cancer, medically treated diabetes with a blood sugar level >250 mg/dL, and inadequate bone marrow function. Outcome measures Postoperative follow-up visits were scheduled 6, 12 and 24 months after surgery. The last 24 months follow-up visit was completed in December 2018. Occurrence of any complications was recorded at these visits. Seroma and Haematoma were assessed irrespective of treatment. The results for the PRO have been previously published.16 One patient could have had more than one complication documented. Only complications judged to be study-relevant by the Clinical Event Committee are included in the analysis. Statistical analysis Statistical analyses were performed with R statistical framework version 3.5.3. (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org/). Continuous risk factors were additionally stratified using age ≥ 50 years to define increased age, BMI of ≥ 25 kg/m2 to define obesity, and implant volume ≥ 75% percentile to define the quarter of implants with the largest volume. The term “First event” defines the first complication occurring in a patient irrespective of the kind of complication. Modelling is based on univariable and multivariable logistic regression as well as cox regression. Kaplan Meier estimate was used for survival analysis of explanted meshes. Odds ratios with 95% confidence intervals (CI) and p-values are reported. A p-value lower than 0.05 is considered statistically significant. No correction for multiple testing was performed. The manuscript was prepared according to the “Strengthening The Reporting Of Observational studies in Epidemiology” (STROBE) checklist for cross-sectional studies.17 Results Demographic and medical history Patients’ demographic and medical history data have been published previously.16 Briefly, 269 patients underwent mastectomy and IBBR with support of TiLOOP® Bra. The mean patient age was 49.3 years (range 19–77 years) and the mean body mass index (BMI) was 23.1 kg/m² (range 17–40 kg/m²). The Charlson Comorbidity Index (CCI) was applied, with 133 (49.4%) of the patients scoring two points and only 12 (4.5%) having no comorbidities (Table 1). Seventy-six patients (28.3%) were excluded after surgery and before 24 months follow-up visit, i.e. due to adverse events leading to TiLOOP® Bra explantation (N = 32, 11.9%), death (N = 1, 0.4%), being lost to follow-up (N = 25, 9.3%), or wish of the patient (N = 18, 6.7%). The 24-months FU was completed by 193 patients (Fig. 1). Reasons for TiLOOP® Bra mesh explantation were capsular fibrosis (N = 12, 4.5%), necrosis (N = 5, 1.2%), DIEP reconstruction (N = 6, 2.2%), infection (N = 3, 1.1%), surgery due to positive margins (N = 3, 1.1%), wound dehiscence (N = 2, 0.7%), and wound healing disturbance (N = 1, 0.4%). Survival analysis revealed that 50% of mesh explantations had already taken place within the first seven months (Fig. 2).Table 1Baseline patient characteristics. Patient, tumour and treatment related characteristics. NA = not available.Table 1 dummy alt textCharacteristicValuePercentage(269 patients total)Age in years: mean (range)49.3 (19–77)–BMI mean (SD; range)23.1 (3.5; 17–40 kg/m2)–≤ 25 kg/m220877.3%> 25 kg/m26122.7%DiabetesNo diabetes26397.8%Diabetes type 110.4%Diabetes type 251.9%Pre-menopausal / menopausalPre-menopausal14955.4%Menopausal11843.9%NA20.7%Charlson Comorbidity Index (CCI)Score 0124.5%Score 110.4%Score 213349.4%Score 36624.5%Score 44014.9%Score 5155.6%Score 620.7%UICC classificationUICC 04817.8%UICC stage I7026.0%UICC stage II10539.0%UICC stage III238.6%UICC stage IV00.0%NA248.9%Radiotherapyno radiotherapy20676.6%preoperative radiotherapy269.7%adjuvant radiotherapy3713.8%Chemotherapyno chemotherapy15055.8%neoadjuvant chemotherapy7829.0%adjuvant chemotherapy4115.2%Fig. 1Flow diagram of the patient cohort. The number of patients at screening, surgery up to the 24 months follow-up as well as the number of excluded patients between the time points is given.Fig 1 dummy alt textFig. 2Kaplan-Meier survival analysis for the explanted meshes.Fig 2 dummy alt text Table 1Baseline patient characteristics. Patient, tumour and treatment related characteristics. NA = not available.Table 1 dummy alt textCharacteristicValuePercentage(269 patients total)Age in years: mean (range)49.3 (19–77)–BMI mean (SD; range)23.1 (3.5; 17–40 kg/m2)–≤ 25 kg/m220877.3%> 25 kg/m26122.7%DiabetesNo diabetes26397.8%Diabetes type 110.4%Diabetes type 251.9%Pre-menopausal / menopausalPre-menopausal14955.4%Menopausal11843.9%NA20.7%Charlson Comorbidity Index (CCI)Score 0124.5%Score 110.4%Score 213349.4%Score 36624.5%Score 44014.9%Score 5155.6%Score 620.7%UICC classificationUICC 04817.8%UICC stage I7026.0%UICC stage II10539.0%UICC stage III238.6%UICC stage IV00.0%NA248.9%Radiotherapyno radiotherapy20676.6%preoperative radiotherapy269.7%adjuvant radiotherapy3713.8%Chemotherapyno chemotherapy15055.8%neoadjuvant chemotherapy7829.0%adjuvant chemotherapy4115.2% Baseline patient characteristics. Patient, tumour and treatment related characteristics. NA = not available. Flow diagram of the patient cohort. The number of patients at screening, surgery up to the 24 months follow-up as well as the number of excluded patients between the time points is given. Kaplan-Meier survival analysis for the explanted meshes. Surgical and cancer-related characteristics Of the 269 patients, the majority (N= 176, 65.4%) underwent unilateral surgery, while 93 patients (34.6%) underwent bilateral surgery (Table 2). Thus, a total of 362 breasts were operated on. Immediate reconstruction was performed on 347 (95.9%) of the 362 breasts, while reconstruction was delayed in 15 breasts (4.1%). Nipple-sparing mastectomy was the most frequently performed procedure (N = 301, 83.1%), while skin-sparing mastectomy was performed on 13.3% of breasts (N = 48). Modified radical mastectomy and other types of mastectomy accounted for 3.6% of breasts (N = 13). Incision techniques were categorised according to Lotan, et al.18 as either “hidden” (inframammary or peri-areolar; N = 168, 62%) or “transverse/vertical” (vertical, t-shaped, hockey stick, tennis racket, radial; N = 89, 33%) incisions. Twelve reconstructions (4%) were not categorised to either of the two groups due to improper description or “use of existing scar”. The implants were mostly textured (359/362, 99.2%) and of anatomic shape (274/362, 75.7%); the mean implant volume was 318.6 cm3 (range 120–750 cm3, 75th percentile = 395 cm3) (Table 3). Most patients (205/269, 76.2%) did not undergo radiotherapy before or after surgery. Twenty-six patients (9.7%) had a history of radiotherapy, and received adjuvant radiotherapy. More than half of the patients (150/269, 55.8%) did not receive any chemotherapy, 78 patients (29.0%) received neoadjuvant, and 41 patients (15.2%) received adjuvant chemotherapy (Table 4).Table 2Surgery related characteristics. Mastectomy and reconstruction specific details are given. NA = not available.Table 2 dummy alt textCharacteristicValuePercentage269 patients total / 362 operated breastsType of mastectomySkin-sparing4813.3%Nipple-sparing30183.1%modified radical20.6%Other113.0%Incision techniquehidden incision16862.5%transverse or vertical incision8933.1%NA124.5%Laterality of reconstructionUnilateral17665.4%Bilateral9334.6%Timing of reconstructionImmediate reconstruction34795.9%Delayed reconstruction154.1%Implant / ExpanderImplant32690.1%Expander369.9%Table 3Multivariable logistic regression of patient and treatment related risk factors contributing to the occurrence of the first event after IBBR.Table 3 dummy alt textAE typeRisk factorOR (95% CI) multivariablep-value multivariableFirst eventneoadjuvant chemotherapy2.56 (1.32–4.95)0.00520978First eventadjuvant chemotherapy1.9 (0.82–4.42)0.135083817First eventImplant volume ≥ 75th percentile1.97 (0.75–5.2)0.169049453First eventBMI1.09 (0.94–1.27)0.262674606First eventadjuvant radiotherapy1.61 (0.58–4.51)0.362755798First eventCCI1.24 (0.71–2.16)0.453446331First eventneoadjuvant radiotherapy0.72 (0.29–1.78)0.472604813First eventAge1.02 (0.96–1.07)0.525489693First eventImplant volume1 (1–1.01)0.556783144First eventBMI ≥ 25 kg/m²0.76 (0.25–2.33)0.634323089First eventAge ≥ 500.92 (0.36–2.35)0.855165205First eventTransverse or vertical incision0.99 (0.54–1.8)0.962563441Table 4Multivariable cox regression of patient and treatment related risk factors contributing to the occurrence of implant loss after IBBR.Table 4 dummy alt textRisk factorhazard ratio (95% CI)p-valueImplant volume1.0033 (0.99854–1.008)0.17Implant volume ≥ 75th percentile1.1135 (0.32951–3.7629)0.86BMI0.97499 (0.82317–1.1548)0.77BMI ≥ 25 kg/m²1.7056 (0.44347–6.56)0.44adjuvant radiotherapy0.84973 (0.28229–2.5578)0.77adjuvant chemotherapy1.6419 (0.65111–4.1402)0.29Age0.9787 (0.91415–1.0478)0.54CCI1.3838 (0.68372–2.8005)0.37 Table 2Surgery related characteristics. Mastectomy and reconstruction specific details are given. NA = not available.Table 2 dummy alt textCharacteristicValuePercentage269 patients total / 362 operated breastsType of mastectomySkin-sparing4813.3%Nipple-sparing30183.1%modified radical20.6%Other113.0%Incision techniquehidden incision16862.5%transverse or vertical incision8933.1%NA124.5%Laterality of reconstructionUnilateral17665.4%Bilateral9334.6%Timing of reconstructionImmediate reconstruction34795.9%Delayed reconstruction154.1%Implant / ExpanderImplant32690.1%Expander369.9% Surgery related characteristics. Mastectomy and reconstruction specific details are given. NA = not available. Table 3Multivariable logistic regression of patient and treatment related risk factors contributing to the occurrence of the first event after IBBR.Table 3 dummy alt textAE typeRisk factorOR (95% CI) multivariablep-value multivariableFirst eventneoadjuvant chemotherapy2.56 (1.32–4.95)0.00520978First eventadjuvant chemotherapy1.9 (0.82–4.42)0.135083817First eventImplant volume ≥ 75th percentile1.97 (0.75–5.2)0.169049453First eventBMI1.09 (0.94–1.27)0.262674606First eventadjuvant radiotherapy1.61 (0.58–4.51)0.362755798First eventCCI1.24 (0.71–2.16)0.453446331First eventneoadjuvant radiotherapy0.72 (0.29–1.78)0.472604813First eventAge1.02 (0.96–1.07)0.525489693First eventImplant volume1 (1–1.01)0.556783144First eventBMI ≥ 25 kg/m²0.76 (0.25–2.33)0.634323089First eventAge ≥ 500.92 (0.36–2.35)0.855165205First eventTransverse or vertical incision0.99 (0.54–1.8)0.962563441 Multivariable logistic regression of patient and treatment related risk factors contributing to the occurrence of the first event after IBBR. Table 4Multivariable cox regression of patient and treatment related risk factors contributing to the occurrence of implant loss after IBBR.Table 4 dummy alt textRisk factorhazard ratio (95% CI)p-valueImplant volume1.0033 (0.99854–1.008)0.17Implant volume ≥ 75th percentile1.1135 (0.32951–3.7629)0.86BMI0.97499 (0.82317–1.1548)0.77BMI ≥ 25 kg/m²1.7056 (0.44347–6.56)0.44adjuvant radiotherapy0.84973 (0.28229–2.5578)0.77adjuvant chemotherapy1.6419 (0.65111–4.1402)0.29Age0.9787 (0.91415–1.0478)0.54CCI1.3838 (0.68372–2.8005)0.37 Multivariable cox regression of patient and treatment related risk factors contributing to the occurrence of implant loss after IBBR. Surgical complications A total of 182 complications occurred in 123 out of 269 patients (45.7%). On the breast level, this equates to 198 affected breasts out of 362 treated breasts (54.7%). Of these patients, 43 (16.0%) experienced more than one complication; three (1.1%) experienced four complications and one patient (0.4%) had five complications. Conversely, 146 patients (54.3%) had no complication. The most frequent complication was capsular fibrosis. A total of 55 breasts (15.1%) in 47 patients were diagnosed with capsular fibrosis and categorised according to the Baker scale. Three capsular fibrosis were assessed as Baker grade I, 18 as Baker grade II, 19 as Baker grade III, and 11 as Baker grade IV. Categorisation according to the Baker scale was unavailable for two cases of capsular fibrosis. The number of significant Baker III and IV capsular fibrosis accounted to 30 (8.2% of breasts). Further complications included seroma (N = 28, 7.7%), necrosis (N = 22, 7.5%), infection/inflammation (N = 20, 5.5%), wound dehiscence (N = 19, 5.2%), other complications (N = 16, 4.4%), haematoma (N = 11, 3.0%), secondary bleeding (N = 9, 2.8%), wound healing disorder (N = 7, 1.9%), implant dislocation (N = 2, 0.6%) and one dysesthesia (0.3%). A total of 94 (51.6%) complications were treated medicinally or conservatively, and 88 (48.4%) complications were treated surgically. For further evaluation, wound healing disorders, wound dehiscence and necrosis were grouped together under the term “wound complications”. Furthermore, the first occurring event was analysed. This group (N = 124) included the following: wound healing disorders (N = 29, 23.0%), capsular fibrosis (N = 27, 22.0%), seroma (N = 23, 19.0%), infection/inflammation (N = 14, 11.0%), haematoma (N = 11, 9.0%), secondary bleeding (N = 9, 7.0%), other (N = 8, 6.0%), implant dislocation (N = 2, 2.0%), and dysesthesia (N = 1, 1.0%). Risk factors for complications Different patient and therapy-related risk factors for the occurrence of complications were analysed. Pre-specified factor according to the clinical investigation plan of the PRO-BRA study was radiotherapy either pre- or postoperatively. Based on current knowledge and clinical relevance the following exploratory risk factors were also defined: BMI (continuously and grouped to < 25 kg/m2 and ≥ 25 kg/m2), age (continuously and grouped to < 50 years and ≥ 50 years), CCI, neoadjuvant chemotherapy (yes/no), adjuvant chemotherapy (yes/no), incision technique (inframammary/peri-areolar [hidden] and vertical/t-shaped/hockey stick/tennis racket/radial [transverse/vertical]), and implant volume (continuously and categorised to < 395 cm3 and ≥ 395 cm3). Radiotherapy and chemotherapy were considered as relevant risk factors if the therapy had commenced prior to the occurrence of the complication. Univariable logistic regression analysis (Fig. 3, Suppl. Table 1, Suppl. Table 2) was applied to analyse the influence of those risk factors on the occurrence of capsular fibrosis, seroma, wound healing disorders, and infection was analysed. Furthermore, the first event to occur for one patient (irrespective of the type of complication) was included in the analysis. For each of the complications at least one risk factor was identified as significantly increasing the odds ratio.Fig. 3Univariable logistic regression. Forest plot showing the different risk factors and their potential impact on occurrence of first event, capsular fibrosis, seroma, and wound complications, infection/inflammation.Fig 3 dummy alt text Univariable logistic regression. Forest plot showing the different risk factors and their potential impact on occurrence of first event, capsular fibrosis, seroma, and wound complications, infection/inflammation. The first event occurred in 60% (N = 38/63) of obese patients (BMI ≥ 25 kg/m2) while 40% (N = 25/63) did not experience any event. The opposite was true for non-obese patients (BMI < 25 kg/m2): 42% (N = 86/206) of non-obese experienced an event while 58% (N = 120/206) did not (OR = 2.1, 95% CI: 1.2–3.8, p = 0.01). Among patients with high-volume implants (≥ 395 cm3) the first event occurred in 63% (N = 43/68) of the patients; among patients with an implant volume < 395 cm3 the first event occurred in only 40% (N = 81/201) of the patients (OR = 2.6, 95% CI: 1.4–4.5; p = 0.001). Of those patients having received adjuvant radiotherapy, 50% (N = 18/36) developed a capsular fibrosis compared to 12% (N = 27/233) of the patients not having undergone adjuvant radiotherapy (OR = 7.6, 95% CI: 3.5–16.4; p < 0.0001). Seroma occurred in 21% (N = 13/63) of obese against 7% (N = 14/206) of non-obese patients (OR = 3.6, 95% CI: 1.6–8.1; p = 0.002), in 16% (N = 20/122) of patients aged 50 years and older compared to 5% (N = 7/147) in patients < 50 years (OR = 3.9, 95% CI: 1.6–9.62, p = 0.003), and in 21% (N = 14/68) of patients receiving an implant ≥ 395 cm3 compared to 6% (N = 13/201) of patients with an implant volume < 395 cm3 (OR = 3.8, 95% CI: 1.7–8.5; p = 0.001). Wound complications were more likely to occur in obese (32%, N = 20/63) than in non-obese (7%, N = 15/206) patients (OR = 5.9, 95% CI: 2.8–12.5; p < 0.0001), and the odds was higher for patients with an implant volume ≥ 395 cm3 (31%, N = 21/68) than in patients with implant volume < 395 cm3 (7%, N = 14/201) (OR = 6.0, 95% CI: 2.8–12.6; p < 0.0001). Furthermore, breast reconstructions involving transverse or vertical incision were more likely to result in wound complications (27%, N = 24/89) compared to inframammary or peri-areolar incision (5%, N = 9/168) (OR = 6.52, 95% CI: 2.88–14.79, p < 0.0001). Patients having received adjuvant chemotherapy more often experienced infections (15%, N = 6/40) compared to patients without adjuvant chemotherapy (6%, N = 13/229) (OR = 2.9, 95% CI: 1.0–8.2; p = 0.04). Previous radiotherapy and neoadjhuvant chemotherapy were not significant risk factors for the occurrence of complications in univariable logistic regression analysis. Multivariable analysis was used to further elucidate the occurrence of the first event irrespective of the type of complication. For the specific complications, no multivariable modelling was performed due to low number of events per group. All potential risk factors were included in the analysis. The only remaining statistically significant risk factor for the occurrence of the first complication was neoadjuvant chemotherapy (OR = 2.6; 95% CI 1.3–5.0; p < 0.01) (Table 3). Multivariable cox regression was applied to illustrate potential factors for implant loss. For none of the factors a significant increased or decreased hazard ratio could be detected (Table 4). Discussion IBBR is a well-established option for breast reconstruction after mastectomy, supporting patients to achieve a positive body image during and after cancer treatment. To avoid insufficient coverage of the prosthesis, supporting materials such as the synthetic TiLOOP® Bra mesh can be used. However, complications such as necrosis, infection, haematoma, secondary bleeding, seroma and wound healing disturbances may affect the postoperative course of implant-based breast reconstruction with synthetic mesh9, 10, 11 and must be considered when selecting the appropriate reconstructive approach. In the prospective, multicentre PRO-BRA study we evaluated complications up to 24 months after IBBR supported by the non-resorbable, titanized polypropylene mesh TiLOOP® Bra. A total of 269 patients were included and 362 breasts were treated. Univariable and multivariable logistic regression analyses were performed to identify patient- and therapy-related risk factors for complications occuring in the postoperative period following IBBR with TiLOOP® Bra support. While some of the risk factors observed in our cohort have been reported previously, the present study provides several important additions to the literature. To our knowledge, it represents one of the largest multicentre, prospective cohorts using TiLOOP® Bra-assisted IBBR. The 24-month follow-up allows us to capture late mesh-related outcomes such as capsular contracture and reconstructive failure. Age and BMI showed univariable associations with complications in our cohort, consistent with previous findings,19,20 but these variables did not remain independently significant in multivariable analysis. Although breast reconstruction in women over 60 years has been shown to be safe and feasible,21 careful preoperative selection and information are required and additional risk factors must be excluded. The CCI was investigated as a potential risk factor for the occurrence of complications. In the present study, patients with a higher CCI score were found to be at an increased risk of developing seroma. A population-based cohort study showed a strong association between the CCI score and undergoing one or more revisions.22 The American Society of Anaesthesiologists (ASA) physical status was shown not to be a predictor of infection23; however, ASA physical status of 3 or more was associated with complications24 and ASA classes 3 and 4 were identified as predictors of readmission.25 In an univariable logistic regression analysis, implant volume was identified as a risk factor for wound complications and seroma formation. Other studies have found an association between an increased weight of removed breast tissue of more than the 75th percentile (438 g,15 434 g26) or more than the mean (548 g),27 respectively, with an increased complication rate. In contrast, in a study of complete submuscular implant reconstructions it has been found that an implant volume greater than the median (390 ml) was not a statistically significant risk factor.28 However, implant volume did not remain independently significant in our multivariable model. The incision site is important not only for the resulting scar, but also as a risk factor for the occurrence of complications. The PRO-BRA study identified transverse or vertical incisions (vertical, t-shaped, hockey stick, tennis racket or radial) as increasing the risk for wound complication (necrosis, wound dehiscence, wound healing disorders) compared to inframammary or peri-areolar incisions. These findings are supported by previous studies. Roh, et al.29 have previously investigated the occurrence of surgical complications in IBBR with inframammary and non-inframammary incisions. They found that skin breakdown/necrosis occurred significantly more often in the non-inframammary fold group than in the inframammary fold group. Kim, et al.30 showed that significantly more necrosis occurred in reconstructions with the radial incision technique compared to inframammary incisions. In the setting of IBBR, adjuvant radiotherapy has widely been discussed as driver for the emergence of complications. Nonetheless, the data are inconsistent.28,31, 32, 33 The results of the PRO-BRA study confirm the findings of several previous studies that adjuvant radiotherapy increases the risk for capsular fibrosis formation. Patients who received adjuvant chemotherapy were at an increased risk of infection. This association has not been described before and may be due to the underlaying condition for receiving adjuvant chemotherapy (tumour size, lymph node metastases), which leads to a more extensive tumour surgery. It is also worth mentioning that four of the six patients had breast implants of more than 395 cm3 which was also identified as a risk factor in this study. Furthermore, previous adverse events may increase the risk of infection, although these effects were not further analysed in this evaluation. Chemotherapy affects the immune system by reducing the number of leukocytes, thereby potentially increasing the susceptibility to infection. Furthermore, chemotherapy affects fibroblast production and collagen synthesis, both of which are essential components for wound healing.34 In the PRO-BRA study, multivariable analysis identified neoadjuvant chemotherapy as independent risk factor for having the first complication. Previous studies have shown that neoadjuvant chemotherapy increases the risk of postoperative infections35,36 and for major complications an increased risk with any type of chemotherapy was shown.37 However, other studies found no association between neoadjuvant chemotherapy and postoperative complications,19,31,38 IBBR failure, or unplanned reoperations.33 Notably, in publications reporting no association between neoadjuvant chemotherapy and complications, the percentage of patients receiving neoadjuvant chemotherapy was only 14%19 and 16%,31 except in one publication where it was 30%.38 By contrast, 29% of the patients in the PRO-BRA study received neoadjuvant chemotherapy, which is comparable to the 24.1% and 28% reported by Anaya, et al.35 and Remington, et al.,37 respectively. At the time of the inclusion and treatment of the patients back in 2013 to 2016, the use of textured implants was standard of care. However, contemporary data on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) suggest that the risk associated with textured implants may outweigh their benefits for many patients.39 Consequently, contemporary implant selection increasingly favours smooth or micro/nano-textured devices, reflecting a re-evaluation of the balance between the benefits of textured surfaces and the now-recognized BIA-ALCL risk. This evolution explains the higher proportion of textured implants in our study cohort and underscores the importance of interpreting our findings within the historical context of implant surface preferences during that period. The study is limited by its single-arm design, thereby not giving insight to IBBR reconstructions without mesh. Despite the limitations inherent to its single‑arm design, this study remains one of the largest prospective cohorts of TiLOOP® Bra‑assisted IBBR, offering extended follow‑up and detailed complication profiling. Given the limited sample size, applying multiple-testing corrections would excessively reduce statistical power. We therefore chose to report unadjusted p-values and transparently acknowledge the risk of false-positive findings. In our view, although reconstructive practice has evolved, the core biological behaviours underpinning mesh‑assisted reconstruction, i.e. tissue response, infection mechanisms, and capsular formation, have remained consistent. Based on this interpretation, we believe that the risk factors and complication patterns described here continue to provide clinically meaningful guidance for contemporary decision‑making. Conclusions Several patient- and therapy-related factors were observed to be associated with the occurrence of complications after IBBR with support of TiLOOP® Bra. In this study, univariable regression analysis identified BMI, implant volume, age, adjuvant radiotherapy and adjuvant chemotherapy as potential factors associated with increased odds of developing complications. Multivariable regression analysis confirmed only neoadjuvant chemotherapy as independent risk factor for experiencing a postoperative complication. These results underscore the importance of careful patient selection transparent counselling, and awareness of systemic therapy exposures when planning mesh‑assisted implant reconstruction. Trial registry: clinicaltrials.gov: NCT01885572, DRKS: DRKS00005342 Authors' contributions Marc Thill: Investigation, Resources, Conceptualization, Writing – Review & Editing, Supervision; Stefan Paepke: Investigation, Resources, Writing – Review & Editing; Evelyn Klein: Investigation, Writing – Review & Editing; Elke Nolte: Methodology, Conceptualization, Writing – Original Draft, Visualization; Jan Forster: Methodology, Formal analysis, Writing – Original Draft; Christine Ankel: Investigation, Resources, Writing – Review & Editing; Claudia Gerber-Schäfer: Investigation, Resources, Writing – Review & Editing; Kristin Baumann: Investigation, Resources, Writing – Review & Editing; Anette Meiré: Investigation, Resources, Writing – Review & Editing; Christine Mau: Investigation, Resources, Writing – Review & Editing; Jens-Uwe Blohmer: Investigation, Resources, Writing – Review & Editing; Andree Faridi: Investigation, Resources, Writing – Review & Editing. Acknowledgements The authors would like to thank all women who participated in the PRO-Bra study and the supporting staff from the participating centres. Ethical approval Ethics approval was obtained from the Institutional ethics committee from the faculty of medicine, Technical University Munich, Germany (# 5890/13) as leading ethics committee as well as from the respective ethics committees from the remaining study sites. Conflict of interest The authors have the following to disclose: Marc Thill: received honoraria for lecture and or consulting fas well as travel reimbursements from Amgen, AstraZeneca, Aurikamed, Biom’Up, Celgene, Clovis, Daiichi Sankyo, Eisai, Genomic Health, Hexal, Lilly, MCI, Medtronic, MSD, Myriad, Neodynamics, Norgine, Novartis, OnkoLive, OmniaMed, pfm Medical, Pfizer, Roche, Tesaro, Teva, RTI Surgical, and trial funding from Genomic Health. Stefan Paepke: is a member of the advisory board of pfm medical ag and received honoraria, support of travel, travel reimbursement and support of surgical workshops. Honoraria and travel reimbursement from, NeoDynamics AB (Sweden), Grünenthal, Deutschland; Novusscientific, Schweden, Triconmed, Deutschland, Roche, Schweiz, Bard (B&D) Deutschland, SamanTree, Schweiz, Sysmex Europe GmBH, Deutschland, Endomag, Cambride UK. Evelyn Klein: has nothing to disclose. Elke Nolte: is a permanent employee of pfm medical gmbh. Jan Forster: is a permanent employee of pfm medical gmbh. Christine Ankel: received honoraria for lecture and or consulting as well as travel reimbursements from pfm medical Claudia Gerber-Schäfer: has nothing to disclose. Kristin Baumann: has nothing to disclose. Anette Meiré: has nothing to disclose. Christine Mau: has nothing to disclose. Jens-Uwe Blohmer: has nothing to disclose. Andree Faridi: is a member of the advisory board of pfm medical ag and received honoraria for lecture and or consulting as well as travel reimbursements from pfm medical and DIZG.